Search

Author/Creator Pietrantonio, F

2. 5PSQ-097 Toxicity associated with gene polymorphisms in patients with colorectal cancer, treated with fluoropyrimidines and analogues, irinotecan and platinum coordination complexes. (2nd March 2018)

Authors:
Cricchio, G Lo; Saibene, G; Ruffino, E; Laganà, G; Costanza, C Della; Pietrantonio, F; Falvella, S; Nichetti, F; Celotti, FM; Ladisa, V
Journal:
European journal of hospital pharmacy
Issue:
Volume 25(2018)Supplement 1
Page Start:
A209
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Device therapy for the major complications detection and early treatment of patients with natural and iatrogenic comorbidities admitted to internal medicine wards. (14th October 2021)

Authors:
Pietrantonio, F; Rosiello, F; Pascucci, M; Alessi, E; Ciamei, A; Cipriano, E; Di Berardino, A; Laurelli, G; Porzano, A; Delli Castelli, M; Marino, G; Onesti, E; Montagnese, F; Rainone, M; Ruggeri, M
Journal:
European heart journal
Issue:
Volume 42(2021)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. LBA20TRIBE2: A phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts). (23rd October 2018)

Authors:
Cremolini, C; Antoniotti, C; Lonardi, S; Rossini, D; Pietrantonio, F; Cordio, S S; Murgioni, S; Marmorino, F; Maiello, E; Passardi, A; Masi, G; Tamburini, E; Santini, D; Grande, R; Zaniboni, A; Granetto, C; Loupakis, F; Delliponti, L; Boni, L; Falcone, A
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. LBA22Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus pan or single-agent pan: Translational analyses of the VALENTINO study. (23rd October 2018)

Authors:
Morano, F; Corallo, S; Di Bartolomeo, M; Lonardi, S; Cremolini, C; Rimassa, L; Sartore Bianchi, A; Murialdo, R; Zaniboni, A; Adamo, V; Tomasello, G; Tampellini, M; Fanchini, L; Schirripa, M; Clavarezza, M; Petrelli, F; Longarini, R; Cinieri, S; de Braud, F G M; Pietrantonio, F
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. O-007Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO. (20th June 2018)

Authors:
Rossini, D; Cremolini, C; Conca, E; Del Re, M; Busico, A; Pietrantonio, F; Bergamo, F; Danesi, R; Cardellino, G; Tamburini, E; Dell'Aquila, E; Strippoli, A; Masi, G; Tonini, G; Negri, F; Corsi, D; Pella, N; Intini, R; Falcone, A; Santini, D
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. O-016First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study. (20th June 2018)

Authors:
Pietrantonio, F; Morano, F; Corallo, S; Raimondi, A; Loupakis, F; Cremolini, C; Smiroldo, V; Berenato, R; Bianchi, A Sartore; Tampellini, M; Bustreo, S; Clavarezza, M; Murialdo, R; Zaniboni, A; Tomasello, G; Peverelli, G; Antoniotti, C; Procaccio, L; Cinieri, S; Antonuzzo, L
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 5
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗